BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Mucolipin 1 (TRPML1; MCOLN1); inositol polyphosphate-5-phosphatase f (INPP5F)

Renal disease INDICATION: Renal damage; renal failure Patient sample and cell culture studies suggest enhancing TRPML1 activity could help treat renal damage and failure associated with Lowe syndrome, which is caused by mutations in INPP5F...
BioCentury | May 21, 2015
Distillery Therapeutics

Therapeutics: Inositol polyphosphate-4-phosphatase type II (INPP4B); phosphatase and tensin homolog deleted on chromosome ten (PTEN; MMAC1; TEP1)

Cancer INDICATION: Thyroid cancer Mouse and human sample studies suggest agonizing INPP4B could help treat PTEN-deficient thyroid cancer. INPP4B levels were lower in thyroid tissues samples from thyroid cancer patients than in samples from control...
BioCentury | Apr 9, 2015
Distillery Therapeutics

Therapeutics: Inositol polyphosphate-5-phosphatase D (INPP5D); spleen tyrosine kinase (SYK)

...ALL. Philadelphia chromosome-positive (Ph+) ALL cells from patients expressed higher levels of receptors that recruit INPP5D...
...cells from patients, vector-mediated expression of a constitutively active SYK variant or a small molecule INPP5D...
...optimizing the INPP5D inhibitor and developing inhibitors of other phosphatases that negatively regulate SYK. TARGET/MARKER/PATHWAY: Inositol polyphosphate-5-phosphatase D (INPP5D)...
BioCentury | May 27, 2010
Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Nerve damage; neurology; stroke Inositol polyphosphate-4-phosphatase type I (INPP4A) A study in mice suggests that increasing INPP4A expression could help prevent excitotoxicity-induced nerve damage that...
BioCentury | Feb 5, 2009
Distillery Therapeutics

Indication: Infectious disease

...marker/ pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection Inositol polyphosphate-5-phosphatase (INPP5D...
BioCentury | Mar 5, 2007
Tools & Techniques

Expanding the HDAC envelope

A pair of recently published papers highlight two possible therapeutic areas for histone deacetylase inhibitors outside of cancer: preventing heart failure and treating spinal muscular atrophy. Several HDAC inhibitors are in Phase II trials for...
Items per page:
1 - 6 of 6